Skip to main content
Clinical Trials/ITMCTR2100004843
ITMCTR2100004843
Recruiting
Phase 1

Electrical stimulation of external auditory canal combined with acupuncture in the treatment of tinnitus of damage of kidney-essnce: a randomized controlled study

Chengdu Renpin Ear, Nose and Throat Specialist Hospital0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
tinnitus of damage of kidney-essnce
Sponsor
Chengdu Renpin Ear, Nose and Throat Specialist Hospital
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Chengdu Renpin Ear, Nose and Throat Specialist Hospital

Eligibility Criteria

Inclusion Criteria

  • 1\. Subjective symptoms of tinnitus (in line with the diagnostic criteria of Chinese Medicine Otorhinolaryngology), tinnitus in one or both ears, with or without hearing loss;
  • 2\. The tinnitus has been recurrent for more than 1 month or lasted more than 5 days;
  • 3\. The first onset time \<\= 5 years;
  • 4\. Aged 18 to 80 years;
  • 5\. Patients with tinnitus with kidney essence loss based on syndrome differentiation;
  • 6\. The informed consent form has been signed.

Exclusion Criteria

  • 1\. Those who are accompanied by ear foreign bodies, inflammation, tumors, deformities, trauma, etc., who are found to be tinnitus caused by space\-occupying lesions by otology examination, as well as objective deafness, total deafness and tinnitus;
  • 2\. There are obvious epidemic and infectious diseases in the near future or before the occurrence of tinnitus, such as herpes zoster auris, meningitis, mumps, measles, etc.;
  • 3\. Those who cooperate with other treatment methods at the same time, or those who still receive other treatments within 2 weeks before the start of this observation;
  • 4\. Patients during pregnancy or lactation, and those who are allergic to drugs;
  • 5\. Patients with severe primary diseases such as heart, liver, kidney and hematopoietic system, mental illness;
  • 6\. Others who do not meet the inclusion criteria and cannot evaluate the efficacy and safety.

Outcomes

Primary Outcomes

Not specified

Similar Trials